补体系统 (Complement System) 由 30 多种血清和细胞表面成分组成,作为先天和后天免疫系统的一部分,参与识别和消除病原体。一旦补体系统被激活,就会发生一系列涉及蛋白水解和组装的反应,导致第三个补体成分 (C3) 裂解。C3 裂解之前的级联称为激活途径。有三种激活途径:经典途径、凝集素途径和替代途径。
补体级联是一把双刃剑,通过促进吞噬作用和炎症来防止细菌和病毒入侵。从病理学上讲,如果补体得不到充分控制,可能会对血管(血管炎)、肾基底膜和附着的内皮细胞和上皮细胞(肾炎)、关节滑膜(关节炎)和红细胞(溶血)造成严重损害。
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
Izastobart 是一种靶向 C5AR1 的 Human IgG1 λ2 单克隆抗体,其同型对照产品为 Human IgG1 lambda2, Isotype Control (MS-A36777)。
RPARPAR 是一种 CendR 肿瘤穿透肽,可直接结合肿瘤细胞表面的 NRP-1 和 NRP-2 受体,触发细胞内化、血管外渗与肿瘤组织穿透,是实现纳米载体靶向 NRP-1 阳性肿瘤的高效配体,可用于肿瘤和药物递送方面的研究。
RPARPAR acetate 是一种 CendR 肿瘤穿透肽,可直接结合肿瘤细胞表面的 NRP-1 和 NRP-2 受体,触发细胞内化、血管外渗与肿瘤组织穿透,是实现纳米载体靶向 NRP-1 阳性肿瘤的高效配体,可用于肿瘤和药物递送方面的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号